{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:15:10Z","timestamp":1788401710545,"version":"build-2803163510"},"reference-count":47,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A palatable direct compression (DC) orally disintegrating tablet (ODT) product of a bitter drug, diphenhydramine (DPH), was developed using an integrated crystal and particle engineering approach. A DPH salt with a sweetener, acesulfame (Acs), DPH-Acs, was synthesized and its solid state properties were comprehensively characterized. Tablet formulation composition and compaction parameters were optimized by employing material sparing techniques. In vivo disintegration time, bitterness, and grittiness of the final ODT product, were evaluated by a taste panel. Physical stability of the ODT tablets was assessed to identify appropriate storage conditions. Phase-pure DPH-Acs exhibited significantly better tabletability and palatability than DPH-HCl. A DC formulation was designed and optimized to obtain a new ODT product with good manufacturability and excellent product characteristics, including fast in vivo disintegration, and acceptable bitterness and grittiness. A new ODT product of DPH with excellent pharmaceutical properties was successfully developed using 15 g of DPH and in two months. This example shows that integrated crystal and particle engineering is an effective approach for developing high quality ODT products using the DC process.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.7b00423","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T18:53:24Z","timestamp":1503341604000},"page":"3399-3408","source":"Crossref","is-referenced-by-count":25,"title":["Expedited Development of Diphenhydramine Orally Disintegrating\nTablet through Integrated Crystal and Particle Engineering"],"prefix":"10.1021","volume":"14","author":[{"given":"Chenguang","family":"Wang","sequence":"first","affiliation":[{"name":"University of Minnesota , , , ,","place":["Minneapolis, Minnesota, United States, 55455"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenye","family":"Hu","sequence":"additional","affiliation":[{"name":"University of Minnesota , , , ,","place":["Minneapolis, Minnesota, United States, 55455"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-5334","authenticated-orcid":true,"given":"Changquan Calvin","family":"Sun","sequence":"additional","affiliation":[{"name":"University of Minnesota , , , ,","place":["Minneapolis, Minnesota, United States, 55455"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"issue":"8","key":"2026090221462620900_cit1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical\nindustry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev.\nDrug Discovery"},{"issue":"9","key":"2026090221462620900_cit2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.drudis.2008.03.001","article-title":"Product-related research: how research can contribute\nto successful life-cycle management","volume":"13","author":"Sandner","year":"2008","journal-title":"Drug Discovery\nToday"},{"issue":"5\u20136","key":"2026090221462620900_cit3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.drudis.2010.01.007","article-title":"The strategy of enantiomer patents\nof drugs","volume":"15","author":"Agranat","year":"2010","journal-title":"Drug Discovery Today"},{"issue":"1","key":"2026090221462620900_cit4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijpharm.2016.07.018","article-title":"Solid-state\ncharacterization of optically pure (+)Dihydromyricetin extracted from\nAmpelopsis grossedentata leaves","volume":"511","author":"Wang","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"3","key":"2026090221462620900_cit5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"3","key":"2026090221462620900_cit6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4155\/ppa.12.29","article-title":"The A to Z\nof pharmaceutical cocrystals:\na decade of fast-moving new science and patents","volume":"1","author":"Almarsson","year":"2012","journal-title":"Pharm. Pat. Anal."},{"issue":"11","key":"2026090221462620900_cit7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nrd2188","article-title":"The trouble\nwith making combination drugs","volume":"5","author":"Simon","year":"2006","journal-title":"Nat. Rev. Drug\nDiscovery"},{"issue":"12","key":"2026090221462620900_cit8","doi-asserted-by":"publisher","first-page":"e49470","DOI":"10.1371\/journal.pone.0049470","article-title":"Polymorphs and prodrugs and salts\n(oh my!): An empirical analysis of \u201csecondary\u201d pharmaceutical\npatents","volume":"7","author":"Kapczynski","year":"2012","journal-title":"PLoS One"},{"key":"2026090221462620900_cit9","doi-asserted-by":"crossref","DOI":"10.1002\/9781118266755","volume-title":"Pharmaceutical lifecycle\nmanagement: making the most of each and every brand","author":"Ellery","year":"2012"},{"issue":"1","key":"2026090221462620900_cit10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41120-016-0003-4","article-title":"Solid form changes during drug development:\ngood, bad,\nand ugly case studies","volume":"2","author":"Newman","year":"2016","journal-title":"AAPS Open"},{"issue":"5\u20136","key":"2026090221462620900_cit11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/j.1552-4604.1983.tb02730.x","article-title":"Diphenhydramine\nin insomniac family\npractice patients: a double-blind study","volume":"23","author":"Rickels","year":"1983","journal-title":"J.\nClin. Pharmacol."},{"issue":"9","key":"2026090221462620900_cit12","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1021\/acs.cgd.6b00771","article-title":"Crystal structure\ndetermination of dimenhydrinate after\nmore than 60 Years: solving salt\u2013cocrystal ambiguity via solid-state\ncharacterizations and solubility study","volume":"16","author":"Putra","year":"2016","journal-title":"Cryst.\nGrowth Des."},{"issue":"4\u20135","key":"2026090221462620900_cit13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1163\/016942410X525678","article-title":"Decoding\npowder tabletability: roles of particle adhesion and plasticity","volume":"25","author":"Sun","year":"2011","journal-title":"J. Adhes. Sci. Technol."},{"issue":"10","key":"2026090221462620900_cit14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1517\/17460441.2014.941802","article-title":"Challenges and emerging\nsolutions in the development\nof compressed orally disintegrating tablets","volume":"9","author":"Al-Khattawi","year":"2014","journal-title":"Expert Opin. Drug Discovery"},{"issue":"2","key":"2026090221462620900_cit15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1208\/s12249-008-9056-6","article-title":"Taste mask,\ndesign and evaluation\nof an oral formulation using ion exchange resin as drug carrier","volume":"9","author":"Bhise","year":"2008","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"2026090221462620900_cit16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejpb.2008.04.004","article-title":"Specific interactions\nbetween diphenhydramine and \u03b1-helical poly (glutamic acid)\u2013A\nnew ion-pairing complex for taste masking and pH-controlled diphenhydramine\nrelease","volume":"70","author":"Agresti","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"2026090221462620900_cit17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1021\/acs.cgd.5b01484","article-title":"Sweet Berberine","volume":"16","author":"Wang","year":"2016","journal-title":"Cryst. Growth Des."},{"issue":"6","key":"2026090221462620900_cit18","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.xphs.2016.04.006","article-title":"Enabling the Tablet Product Development\nof 5-Fluorocytosine by Conjugate Acid Base Cocrystals","volume":"105","author":"Perumalla","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"2026090221462620900_cit19","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/jps.23876","article-title":"Enabling Tablet\nProduct Development of 5-Fluorocytosine\nThrough Integrated Crystal and Particle Engineering","volume":"103","author":"Perumalla","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"2026090221462620900_cit20","unstructured":"FDA-CDER.\n          \n          Guidance for industry-quality\nattribute\nconsiderations for chewable tablets. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM507098.pdf, 2016."},{"issue":"1","key":"2026090221462620900_cit21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ijpharm.2015.12.022","article-title":"Investigation\nof surface porosity measurements and compaction pressure\nas means to ensure consistent contact angle determinations","volume":"498","author":"Holm","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"1","key":"2026090221462620900_cit22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.powtec.2010.03.011","article-title":"Setting\nthe bar for powder flow properties in successful high speed tableting","volume":"201","author":"Sun","year":"2010","journal-title":"Powder Technol."},{"key":"2026090221462620900_cit23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.powtec.2015.04.004","article-title":"Dependence\nof ejection force on tableting speed\u2500A compaction simulation\nstudy","volume":"279","author":"Sun","year":"2015","journal-title":"Powder Technol."},{"issue":"5","key":"2026090221462620900_cit24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/jps.2600590523","article-title":"Determination of tablet\nstrength by the diametral-compression\ntest","volume":"59","author":"Fell","year":"1970","journal-title":"J. Pharm. Sci."},{"key":"2026090221462620900_cit25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.powtec.2015.11.044","article-title":"Quantifying\neffects of moisture content on flow properties of microcrystalline\ncellulose using a ring shear tester","volume":"289","author":"Sun","year":"2016","journal-title":"Powder\nTechnol."},{"issue":"6","key":"2026090221462620900_cit26","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.xphs.2016.04.006","article-title":"Enabling the tablet product development\nof 5-fluorocytosine by conjugate acid base cocrystals","volume":"105","author":"Perumalla","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"1\u20132","key":"2026090221462620900_cit27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2015.02.061","article-title":"Validation and applications\nof an expedited tablet\nfriability method","volume":"484","author":"Osei-Yeboah","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"4","key":"2026090221462620900_cit28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1081\/PDT-100102041","article-title":"In vitro\ndetermination of disintegration time of quick-dissolve\ntablets using a new method","volume":"5","author":"Dor","year":"2000","journal-title":"Pharm. Dev. Technol."},{"issue":"3","key":"2026090221462620900_cit29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1081\/PDT-120005732","article-title":"Evaluation of disintegration testing of different fast\ndissolving tablets using the texture analyzer","volume":"7","author":"El-Arini","year":"2002","journal-title":"Pharm. Dev. Technol."},{"issue":"1","key":"2026090221462620900_cit30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3109\/10837450.2012.685658","article-title":"Characterization, optimization\nand process robustness of a co-processed mannitol for the development\nof orally disintegrating tablets","volume":"18","author":"Soh","year":"2013","journal-title":"Pharm. Dev.\nTechnol."},{"issue":"2","key":"2026090221462620900_cit31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ijpharm.2013.03.047","article-title":"Prediction of oral disintegration\ntime of fast disintegrating\ntablets using texture analyzer and computational optimization","volume":"448","author":"Szakonyi","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"1","key":"2026090221462620900_cit32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijpharm.2004.08.019","article-title":"Determination\nof the in vitro disintegration profile\nof rapidly disintegrating tablets and correlation with oral disintegration","volume":"292","author":"Abdelbary","year":"2005","journal-title":"Int. J. Pharm."},{"issue":"3","key":"2026090221462620900_cit33","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jconrel.2012.05.026","article-title":"Modeling\nthe oral cavity: in vitro and in vivo evaluations\nof buccal drug delivery systems","volume":"161","author":"Patel","year":"2012","journal-title":"J. Controlled\nRelease"},{"issue":"3","key":"2026090221462620900_cit34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3109\/03639048209022105","article-title":"Equilibrium moisture content of pharmaceutical\nexcipients","volume":"8","author":"Callahan","year":"1982","journal-title":"Drug Dev. Ind. Pharm."},{"key":"2026090221462620900_cit35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/jps.20531","article-title":"Reduced\ntabletability of roller compacted granules\nas a result of granule size enlargement","volume":"95","author":"Sun","year":"2006","journal-title":"J.\nPharm. Sci."},{"issue":"8","key":"2026090221462620900_cit36","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1002\/jps.22118","article-title":"Roles of\ngranule size in over-granulation\nduring high shear wet granulation","volume":"99","author":"Shi","year":"2010","journal-title":"J. Pharm.\nSci."},{"issue":"5","key":"2026090221462620900_cit37","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s11095-016-1858-8","article-title":"A critical examination of the phenomenon\nof bonding area-bonding strength interplay in powder tableting","volume":"33","author":"Osei-Yeboah","year":"2016","journal-title":"Pharm. Res."},{"key":"2026090221462620900_cit38","unstructured":"FDA-CDER.\n          \n          Guidance for Industry-Orally\nDisintegrating\nTablets. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070578.pdf, 2008."},{"issue":"8","key":"2026090221462620900_cit39","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s11095-016-1946-9","article-title":"Pediatric\ndispersible tablets: a modular approach for rapid prototyping","volume":"33","author":"Buck","year":"2016","journal-title":"Pharm. Res."},{"issue":"1","key":"2026090221462620900_cit40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijpharm.2015.03.023","article-title":"Characterising\nthe disintegration properties of tablets\nin opaque media using texture analysis","volume":"486","author":"Scheuerle","year":"2015","journal-title":"Int.\nJ. Pharm."},{"issue":"3","key":"2026090221462620900_cit41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/10837450.2013.775154","article-title":"Why is mannitol\nbecoming\nmore and more popular as a pharmaceutical excipient in solid dosage\nforms?","volume":"19","author":"Ohrem","year":"2014","journal-title":"Pharm. Dev. Technol."},{"issue":"1","key":"2026090221462620900_cit42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijpharm.2015.02.023","article-title":"Effect of granule properties\non rough mouth feel and palatability of orally disintegrating tablets","volume":"484","author":"Kimura","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"9","key":"2026090221462620900_cit43","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1002\/jps.21288","article-title":"Quantifying effects\nof particulate properties on powder\nflow properties using a ring shear tester","volume":"97","author":"Hou","year":"2008","journal-title":"J.\nPharm. Sci."},{"issue":"1","key":"2026090221462620900_cit44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/jps.21422","article-title":"Development of a high drug load tablet formulation\nbased on assessment of powder manufacturability: Moving towards quality\nby design","volume":"98","author":"Sun","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"2026090221462620900_cit45","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1002\/jps.22677","article-title":"Profoundly\nimproving flow properties of a cohesive\ncellulose powder by surface coating with nano silica through comilling","volume":"100","author":"Chattoraj","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"2026090221462620900_cit46","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.powtec.2013.08.031","article-title":"Improving manufacturability\nof an ibuprofen powder blend by surface coating with silica nanoparticles","volume":"249","author":"Zhou","year":"2013","journal-title":"Powder Technol."},{"key":"2026090221462620900_cit47","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1208\/s12249-016-0699-4","article-title":"Role of\nwater sorption\nin tablet crushing strength, disintegration, and dissolution","volume":"18","author":"Sacchetti","year":"2017","journal-title":"AAPS PharmSciTech"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.7b00423","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/14\/10\/3399\/67090859\/acs.molpharmaceut.7b00423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/14\/10\/3399\/67090859\/acs.molpharmaceut.7b00423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:49:33Z","timestamp":1788400173000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/14\/10\/3399\/679365\/Expedited-Development-of-Diphenhydramine-Orally"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,8,21]]},"published-print":{"date-parts":[[2017,10,2]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00423","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]}}}